We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-1.29%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.33B
AUM Growth
+$549M
Cap. Flow
-$84M
Cap. Flow %
-3.6%
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65

Top Buys

Rank Stock Value
1
WY icon
Weyerhaeuser
WY
+$59M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$33.1M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.18M
4
AGN
Allergan plc
AGN
+$6.91M
5
PSTV icon
Plus Therapeutics
PSTV
+$6.73M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$12.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$8.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.12M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.23M
5
TMO icon
Thermo Fisher Scientific
TMO
+$4.64M

Sector Composition

Rank Sector Weight
1 Healthcare 9.43%
2 Real Estate 2.82%
3 Energy 0.36%
4 Consumer Discretionary 0.23%
5 Communication Services 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
26
CALL
Gilead Sciences
GILD
$166B
$16.6M 0.71%
3,006
+13
+0.4% +$1.01K
ABBV icon
27
PUT
AbbVie
ABBV
$470B
$15.3M 0.66%
2,712
-267
-9% -$14K
SGMO
28
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$15.3M 0.66%
10,012
+2
+0% +$29
BIIB icon
29
PUT
Biogen
BIIB
$31.6B
$15M 0.64%
477
+427
+854% +$129K
GEVA
30
PUT
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$13.9M 0.6%
1,331
– –
REGN icon
31
Regeneron Pharmaceuticals
REGN
$73B
$13.6M 0.58%
48,177
+30,986
+180% +$9.18M
ACAD icon
32
Acadia Pharmaceuticals
ACAD
$4.46B
$13.3M 0.57%
589,264
+126,118
+27% +$2.63M
AMGN icon
33
PUT
Amgen
AMGN
$213B
$13.2M 0.56%
1,113
-25
-2% -$2.89K
TPH
34
PUT
DELISTED
Tri Pointe Homes
TPH
$12.4M 0.53%
+7,886
New +$127K
ACHN
35
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$12.1M 0.52%
15,987
+1,294
+9% +$5.16K
TENX icon
36
Tenax Therapeutics
TENX
$419M
$11.1M 0.48%
85
+19
+29% +$2.93M
OPK icon
37
Opko Health
OPK
$1.17B
$10.6M 0.45%
1,193,955
+362,718
+44% +$3.17M
OUT icon
38
PUT
Outfront Media
OUT
$5.78B
$9.32M 0.4%
+2,004
New +$47.2K
BMY icon
39
PUT
Bristol-Myers Squibb
BMY
$130B
$9.19M 0.39%
1,894
+1,722
+1,001% +$84.9K
AEGR
40
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$8.66M 0.37%
+2,700
New +$101K
AZN icon
41
CALL
AstraZeneca
AZN
$270B
$8.56M 0.37%
+1,152
New +$83.3K
IOC
42
DELISTED
Interoil Corporation
IOC
$8.43M 0.36%
131,794
+89,433
+211% +$5.71M
CLVS
43
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$8.27M 0.35%
1,998
+67
+3% +$3.45K
AUXL
44
CALL
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$7.7M 0.33%
3,839
-144
-4% -$3.3K
AGN
45
DELISTED
Allergan plc
AGN
$7.45M 0.32%
+33,376
New +$6.91M
AZN icon
46
PUT
AstraZeneca
AZN
$270B
$7.37M 0.32%
+992
New +$71.7K
ALKS icon
47
CALL
Alkermes
ALKS
$8.48B
$7.05M 0.3%
1,401
+1,228
+710% +$56.6K
CDMO
48
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$7.03M 0.3%
41,657
+7,599
+22% +$95.8K
BMY icon
49
CALL
Bristol-Myers Squibb
BMY
$130B
$6.85M 0.29%
1,413
-15,258
-92% -$752K
ALNY icon
50
PUT
Alnylam Pharmaceuticals
ALNY
$38.7B
$6.8M 0.29%
+1,076
New +$64K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2014 Portfolio in Review

As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sabby Management withdrew a net $84M in Q2 2014, closing 65 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, down from 10% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Sabby Management opened a new position in Weyerhaeuser worth $64.6M.

  • Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
  • Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
  • Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
  • Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
  • Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
  • Sabby Management opened 83 new positions and closed 65 in Q2 2014.
  • Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.

Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.